Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shegan zhike
- Development stage
- Phase 1
- Lead developer
- Liaoning Provincial Academy of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Shegan Zhike is a Traditional Chinese Medicine (TCM) botanical drug candidate developed as a capsule for the treatment of post-infectious cough. The formulation is based on traditional herbal knowledge, likely featuring *Belamcanda chinensis* (Shegan) as a key component, which is traditionally utilized for its antitussive, expectorant, and anti-inflammatory properties. It is currently undergoing Phase I clinical evaluation in China to assess its safety and tolerability in healthy human subjects. The development is sponsored by the Liaoning Provincial Academy of Traditional Chinese Medicine, also known as the Affiliated Second Hospital of Liaoning University of Traditional Chinese Medicine.
- Other names
- Shegan Zhike Capsules射干止咳胶囊
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on shegan zhike.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shegan zhike.